Clinical trial
Remission and Joint Damage Progression in Early Rheumatoid Arthritis
NCT00122382 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00122382 |
|---|---|
| Title | Remission and Joint Damage Progression in Early Rheumatoid Arthritis |
| Official title | A Phase IIIB Multi-center, Randomized, Double-Blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate Naive Early Erosive RA Subjects Treated With Abatacept Plus Methotrexate Compared With Methotrexate |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | Abatacept, placebo, methotrexate |
| Enrollment | 1,052 |
| Start date | Jul 1, 2005 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2009 |
| First posted | Jul 22, 2005 |
| Last update posted | Nov 16, 2010 |
| Countries | Australia, Belgium, Brazil, Canada, Czechia, France, Germany, Italy, Mexico, Netherlands, Poland, Puerto Rico and 6 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: